Breaking: FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1

Preview text: SR Narcolepsy News 5.11.2026 + unexpected cells linked to brain attacks, new Hypersomnia…

Sleep ReviewThursday, Aug 6, 2026 at 10:58 AM EasternHubSpot
Sleep ReviewBreaking: FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1
Subject
Breaking: FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1
Preview text
SR Narcolepsy News 5.11.2026 + unexpected cells linked to brain attacks, new Hypersomnia…
From
news@sleepreviewmag.com
Sent
Thu Aug 6, 2026, 10:58 AM ET
Size
56 KB
Images
10
Links
22, 5 of them buttons
Subject length
73 characters

Against Sleep Review's usual

Sent in the 10 AM hour, which holds 4% of its emails; 20% arrive in the 8 AM hour. The subject is 73 characters; its average is 51.

Email headers

What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.

From
Sleep Review <[email protected]>
Subject
Breaking: FDA Approves First Orexin-Targeting Drug for Narcolepsy Type 1
Date
Thu, 6 Aug 2026 09:58:39 -0500
Message-ID domain
bf56x.hubspotemail.net
Return-Path domain
bf56x.hubspotemail.net
DKIM signature
d=bf56x.hubspotemail.net s=hs1; d=sleepreviewmag.com s=hs2-3426729
List-Unsubscribe
Present, one-click
Feedback-ID sender
HubSpot

Servers it passed through, newest first

  1. from bd77g5q.bf56x.hubspotemail.net [143.244.94.12] by our receiving server with ESMTPS

Other sending headers (names only): X-HS-Cid, X-Report-Abuse-To

Report this email

Sent just before and after

More from Sleep Review

All Sleep Review emails

Get the Black Friday insights

We're collecting every Black Friday email from more than 50,000 brands as it lands. Get what we find: who starts first, the biggest discounts, and the subject lines that stand out.

Free. Unsubscribe anytime.